Lihua Zhang Email

Director, Pharmaceutical Development . QED Therapeutics

Current Roles

Employees:
44
Revenue:
$3.4M
About
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
QED Therapeutics Address
421 Kipling St.
Palo Alto, CA
United States
QED Therapeutics Email

Past Companies

QED TherapeuticsDirector, Pharmaceutical Development
GlaxoSmithKline Pharma GmbHManager
GlaxoSmithKline Pharma GmbHInvestigator

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.